

2026 Benefits and Contributions Launch

09 October 2025



MORE THAN A MEMBER. MORE WITH BANKMED.

AGENDA

08:00 - 09:00

Full buffet breakfast will be served

09:00 - 09:10

Welcome and setting the Scene

Michelle Bam
MC

09:10 - 09:40

Opening Address

Teddy Mosomothane
Bankmed PO/CEO

09:40 - 10:20

2026 Benefits and Contributions

Dr. Niri Naidoo
Clinical and Operations Executive

10:20 - 10:30

New Developments

Teddy Mosomothane
Bankmed PO/CEO

10:30 - 10:40

Client Management update

Jannus Van Der Walt
Senior Manager: Client Management

10:40 - 11:00

Competition and Q&A

Michelle Bam
MC



Opening Address

Teddy Mosomothane

Principal Officer / Chief Executive Officer



MORE THAN A MEMBER. MORE WITH BANKMED.

Acknowledging Our Valued Partners



1

Members



2

**Employer
Group Clients**



3

**Trustees and Scheme
Management**



4

**Outsourced
service partners**



5

**Colleagues and
business associates**



You Are In Good Company

33

Clients



strate



ICAP Holdings SA



Lesaka

BeztForex

SA3RIC

STANLIB

PAY INC



obs ombudsman for banking services
SOUTH AFRICA
Banking
Adjudicator

MOTORITE ADMINISTRATORS

Taquanta



Bidvest Bank

Recalibrating The Balance



A Medical Scheme's Regulatory Requirement

Non-Profit



Sustainability



Bankmed's Purpose




To be an affordable Medical Scheme that guarantees best-of-class member experience, value and quality



Bankmed Values



Our Journey so far & Emerging Realities




In Good Health For Your Good Health

Beneficiaries:

221 531


Market Share



Principal Members:

107 718

Market Share



Average age of Beneficiaries

Bankmed	2023	2024
	32.62	32.87
Industry	2023 Restricted Schemes	2023 All Schemes
	31.83	34.17

32.62



Pensioner Ratio

Bankmed	2023	2024
	8.99%	9.14%
Industry	2023 Restricted Schemes	2023 All Schemes
	7.07%	9.55%

8.99%

6 Benefit Options



AA+ 

Global Credit Rating:
“Very strong financial
security characteristics”

15th year in 2025

In Good Health For Your Good Health

Annual Gross Contribution Income



2023	2024
R6.29 Billion	R6.78 Billion

“Net Surplus/(Deficit)”*: cleared to Insurance Service Result



2023	2024
R6.30 Million*	(R96.39 Million)*

Directly Attributable insurance service Expenditure (DAE) as a % of Insurance Revenue (IR)



Bankmed	2023	2024
	4.24%	4.19%

Industry	2023 Restricted Schemes	2023 All Schemes
	4.07%	7.08%



4.24%

Reserves



	BANKMED		Restricted Schemes Average		Industry
	2023	2024	2023		2023
Reserves	R3.34 Billion	R3.25 Billion	R63.9 Billion		R116.5 Billion
Reserve Ratio	48.98%	43.23%	56.64%	 48.98%	43.45%
Claims Ratio	100.94%	102.41%	98.71%	 100.94%	95.88%

Reserve Ratio | 2020-2025



Year	Reserve Ratio
2020	50.7 %
2021	53.6 %
2022	53.3 %
2023	49.0 %
2024	43.2 %
2025 (forecast)	37.1 %



Better Value




Conclusion by Alexandre Forbes (“Alexforbes”):


- “Overall, the calculations and methodology applied when calculating these measures are deemed appropriate and the 2023 relative value figures shown by NMG are deemed a reasonable reflection of the value of Bankmed’s benefit offering.”
- “The report also contains a BERICO analysis, in which Alexforbes calculated the benefit richness of each of Bankmed’s options and comparable options in the open market. It was found that each of Bankmed’s options offer relatively higher richness compared to options charging similar contribution rates, or relatively lower contributions compared to options offering similar benefit richness. Bankmed’s products are even more valuable for lower income groups, who are able to enjoy rich benefits for relatively low contributions.”

Best-of-class Member Experience

At our Annual General Meeting in June 2025, we shared with you some insights and evidence on how our key service partner deploys our engagement ecosystem to honour our commitment to best-of-class member experience (as explicitly expressed in our purpose).




Membership Administration 2024



Quality Of Our Offering



BANKMED OVER TIME



Quality of care is the degree to which health services for individuals and populations increase the likelihood of the desired health outcome


Focusing on the Emerging Realities



The Unrelenting Claims Experience

The in-hospital claims variance was primarily driven by:


- High-cost cases including paediatric admissions and long-stay ICU cases resulting from cardiac and neurosurgery amongst others;
- More admissions to ICU and high care outside of these high-cost cases as well as more surgical admissions; and
- Some additional admissions resulting from respiratory infection spikes in the first quarter of the year, winter (July) and the last quarter (October, November).



The Unrelenting Claims Experience

The out of hospital variances (risk claims only, not savings) were driven by:

- The spike in respiratory infections as outlined above;
- Increased utilisation of both diagnostics (pathology and radiology) in general as well as high-cost radiological scans; and
- Specifically higher claims cost on the Traditional and Comprehensive plans.
- The latest available industry report that was released by the Council for Medical Schemes relates to the 2023 annual financial year. Although this is now dated, it does enable us to take note of how Bankmed compares to the industry.
- Our claims ratio in 2023 was 100.94%, compared to the overall industry average of 95.88% (the average for restricted medical schemes like Bankmed was 98.71%).
- The claims ratio for Bankmed in 2024 increased to from 100.94% to 102.41%, and the solvency ratio decreased by more than five percentage points from 48.98% in 2023 to 43.23% in 2024, flowing from a shift from a net surplus of R6.3 million in 2023 to a net deficit of R96.4 million in 2024. These are clear indicators of the need to take steps to protect the sustainability of the Scheme, sooner than later.



Reserve Ratio | 2020-2025



Year	Reserve Ratio
2020	50.7 %
2021	53.6 %
2022	53.3 %
2023	49.0 %
2024	43.2 %
2025 (forecast)	37.1 %

Bankmed's Purpose



To be an affordable Medical Scheme that guarantees best-of-class member experience, value and quality



Conclusion

The unrelenting claims experience has required that we recalibrate the balance across a number of factors, to protect Bankmed's sustainability, while staying true to our purpose. This has therefore informed the recalibration of benefits and contribution increases for 2026.



Benefits and Contributions

Dr. Niri Naidoo

Clinical & Operations Executive



MORE THAN A MEMBER. MORE WITH BANKMED.

DISCLAIMER

Bankmed Medical Scheme benefit changes and contribution increases approved by the Bankmed Board of Trustees in compliance with all governance processes.

***Bankmed Medical Scheme benefit changes and contribution increases subject to the Council for Medical Schemes (CMS) approval.**



2026 Contribution Increases



Average Contribution Increases | 2011 – 2025




Bankmed vs Seven Open Schemes

	Bankmed	Average Open Schemes
2011	7.2%	10.2%
2012	7.1%	9.1%
2013	6.9%	9.2%
2014	6.9%	9.1%
2015	7.9%	9.5%
2016	7.8%	9.4%
2017	7.8%	11.0%
2018	8.1%	9.9%
2019	7.9%	10.0%
2020	7.3%	9.7%
2021	3.6%	5.5%
2022	3.2%	5.1%
2023	7.7%	7.7%
2024	8.5%	10.4%
2025	8.7%	10.6%

Open Schemes included: DHMS, Bonitas, Momentum, Bestmed, Medihelp, Medshield, Fedhealth



Average Contribution Increases | 2026 | Industry



2026 Bankmed Contribution | Increases

Plan	2021 Increase	2022 Increase	2023 Increase	2024 Increase	2025 Increase	2026 Increase
Essential	2.5%	1.0%	6.5%	6.1%	5.0%	0.0%
Basic	2.5%	1.0%	6.5%	7.3%	6.0%	7.0%
Core Saver	3.5%	3.5%	7.9%	8.7%	8.8%	7.5%
Traditional	3.5%	3.5%	7.9%	8.7%	8.8%	7.9%
Comprehensive	3.9%	3.5%	7.9%	8.7%	8.8%	7.5%
Plus	3.9%	3.5%	8%	8.7%	9.0%	7.9%
Average	3.6%	3.2%	7.7%	8.5%	8.4%	7.4%

Annual limits of many medical categories were **increased** generally by **4.25%**

Health Quality Assessment (HQA)



What Is Health Quality Assessment?

- **Benchmarking exercise** in the funding industry
- **Highlights key quality issues** in the SA medical scheme industry
- **Drives improvement** in the delivery of evidence-based medicine
- **19 schemes** participated in **2024 HQA** from seven different Administrators
- Comprised of 121 benefit options
- Represented 7,17 million beneficiaries (**82,10% of the medical scheme population**)
- 220 Indicators in four categories were evaluated, namely:
 - Prevention and Screening
 - Hospitalisation
 - Maternity and Newborn
 - Chronic Disease Management



Bankmed Compared to Industry | 2024



Primary Care (Including Screening)

		Bankmed		Industry Benchmark	
Indicator		2024	2023	2024	2024
Prevention	Flu vaccine coverage > = 65years (%)	28.73%	25.34%	21.27%	44%
	Pneumococcal vaccine coverage ≥ 65 years old (%)	14.42%	14.92%	5.89%	N/A
Screening	Cervical Cytology coverage (previous 3 years) (%)	36.19%	35.43%	30.24%	70%
	Mammogram coverage (ages 50-74 years in previous 2 years) (%)	43.24%	39.81%	24.78%	67%
	Bone densitometry coverage for all females aged 65 years or older (%)	26.13%	20.97%	9.22%	N/A
	Colorectal cancer screening ≥ 50 years in previous year (FOBT, %)	1.79%	1.84%	1.10%	N/A
	Percentage of beneficiaries ≥ 2 years old visiting dentists	30.47%	30.02%	23.12%	N/A

Bankmed Compared to Industry | 2024



Chronic Disease Management

		Bankmed		Industry Benchmark	
Indicator		2024	2023	2024	2024
Diabetes	HbA1c coverage for Diabetic patients (%)	72.01%	69.53%	73.63%	67.2%
	Cholesterol related tests coverage for Diabetic patients (%)	74.49%	72.72%	69.86%	87%
	Monitoring Nephropathy for Diabetic patients (%)	77.29%	75.81%	78.04%	95.7%
	Podiatrist cover (%)	7.16%	6.86%	4.18%	68.5%
	Statin coverage (%)	67.05%	66.19%	66.21%	80.6%
	% of Hypoglycaemia related hospital events	0.56%	0.62%	0.68%	N/A
	Lower Limb amputations per 1 000 Diabetics	3.35	3.85	3.38	N/A

Bankmed Compared to Industry | 2024



Chronic Disease Management

		Bankmed		Industry	Benchmark
Indicator		2024	2023	2024	2024
Ischaemic Heart Disease	Aspirin coverage for IHD beneficiaries (%)	90.75%	90.69%	78.45%	88.6%
	Cholesterol test coverage for IHD beneficiaries (%)	76.38%	74.77%	66.20%	88.9%
	Statin Coverage for IHD beneficiaries (%)	86.26%	85.82%	80.73%	N/A
	Beta blocker coverage	56.59%	56.65%	54.68%	90%
	Flu coverage of IHD registered beneficiaries	25.18%	21.89%	21.11%	39.1%
Asthma	Lung function test coverage	13.63%	13.61%	9.86%	40%
	Flu vaccine coverage	13.72%	12.31%	12.59%	45.1%

Bankmed Compared to Industry | 2024




Maternal and New-born

		Bankmed		Industry
Indicator		2024	2023	Industry
Maternal and New-born	Number of Teenage Pregnancy (10-19 years inclusive) cases per 1 000 teenage beneficiaries	1.25	1.35	2.87
	TSH Coverage in New Borns (≤ 6 weeks old) (%)	96.00%	94.17%	80.97%
	Hepatitis B serology coverage during pregnancy	73.71%	72.24%	57.34%
	HIV Screening during pregnancy	82.46%	78.85%	64.51%
	Haemoglobin (Hb) test coverage during pregnancy	90.13%	88.61%	80.62%
	Caesarean Section rate	77.73%	78.02%	75.69%


HQA | Bankmed vs Industry




PRIMARY CARE




MATERNITY



HIV




CHRONIC DISEASES



HQA | Bankmed vs Industry



BANKMED OVER TIME



Quality of care is the degree to which health services for individuals and populations increase the likelihood of the desired health outcome



Benefits Video

New Developments

Teddy Mosomothane

Principal Officer / Chief Executive Officer



MORE THAN A MEMBER. MORE WITH BANKMED.

New Developments



- ✦ **“Resignees” now eligible to stay on Bankmed if they so wish (subject to terms and conditions);**
 - ✦ The definition of a restricted medical scheme provides for former employees (in general);
 - ✦ In June 2024, Bankmed applied for the rules to be changed to cater for those who resign voluntarily from an employer group client, but wish to stay on Bankmed;
 - ✦ On 7 October 2024 the Council for Medical Schemes (CMS) rejected the proposed rule change, and the Scheme appealed against that decision;
 - ✦ Bankmed’s case was heard on 10 April 2025;
 - ✦ A ruling was made in Bankmed’s favour on 13 August 2025;
 - ✦ The effective date of the application of the rule change is still outstanding from the CMS.

New Developments



✦ Balance Enhancements

A woman with dark, wavy hair and glasses, wearing a light pink blazer over a white top, is sitting at a wooden desk in a modern office. She is smiling and looking at a laptop. The background shows a dark wall with three hanging light bulbs and a potted plant.

WATCH THIS SPACE

Client Management Update

Jannus van der Walt

Senior Manager | Client Management



MORE THAN A MEMBER. MORE **WITH BANKMED.**

Rollout and Support



2026
Benefit &
Contribution
Launch
Rationale



Employee
Wellbeing
& Human
Capital
Community
Upskilling




Employer Internal
Communication
Channels



Planned &
Approved Onsite
& Online
Presentations
Supported
by Virtual
1-1 Consultations



National
Roadshow for
Retirees



Online Plan
Selection Guide
Supported by
FAIS Accredited
Consultants



Fieldwork &
Festive Season
Closure
6 October
2025 to
16 January
2026

Competition and Q&A

Michelle Bam

MC / Head of Client Management



 **Bankmed**
Yours in good health

MORE THAN A MEMBER. MORE WITH BANKMED.

Thank you



www.bankmed.co.za



0800 BANKMED (0800 226 5633)



<https://www.facebook.com/BankmedSA/>



https://x.com/Bankmed_SA



Bankmed App



LinkedIn



Instagram



AskBankmed



<https://www.youtube.com/@bankmedmedicalscheme9490>



MORE THAN A MEMBER. MORE WITH BANKMED.